Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Paternal exposure to selective serotonin reuptake inhibitors (SSRIs) prior to conception appears to be associated with a mildly increased risk of attention-deficit/hyperactivity disorder (ADHD) in offspring, according to a study.
Children with attention-deficit/hyperactivity disorder (ADHD) who were bullied tend to suffer more pain and related functional impairment than nonvictims, leading to depression, anxiety, and poor sleep quality, suggests a study presented at the ASEAPS 2017 in Yangon, Myanmar.
High levels of vitamin D in the umbilical blood, due to maternal vitamin D intake during pregnancy, were associated with fewer attention deficit hyperactivity disorder (ADHD) symptoms in the children at 2.5 years, suggesting a protective effect of vitamin D against ADHD in toddlers, according to data from the OCC* study.
Attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) appear to occur with greater frequency in children with allergic diseases, such as atopic dermatitis, asthma, and allergic rhinitis than in those who do not have the diseases, researchers reported.
A novel psychosocial intervention called Collaborative Life Skills (CLS) is effective in reducing attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms, experts say.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.